Cholinergic urticaria
disease diseaseOn this page
Summary
Cholinergic urticaria (MONDO:0006534) is a disease and 7 clinical trials. Top therapeutic interventions include dupilumab, barzolvolimab, and ligelizumab. A subtype of physical urticaria — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 7
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cholinergic urticaria |
| Mondo ID | MONDO:0006534 |
| EFO | EFO:1000679 |
| DOID | DOID:14443 |
| ICD-10-CM | L50.5 |
| ICD-11 | 855107748 |
| SNOMED CT | 73098005 |
| UMLS | C0152230 |
| MedGen | 508939 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of physical urticaria. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › urticaria › physical urticaria › cholinergic urticaria
Related subtypes (2): vibratory urticaria, familial dermatographia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 7.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
| PHASE1 | 2 |
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02012387 | PHASE2 | COMPLETED | Efficacy Study of Omalizumab in Cholinergic Urticaria |
| NCT03749148 | PHASE2 | COMPLETED | Cholinergic Urticaria - Efficacy of Dupilumab |
| NCT04853992 | PHASE2 | COMPLETED | Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria |
| NCT04513548 | PHASE1 | TERMINATED | Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria |
| NCT04548869 | PHASE1 | COMPLETED | A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria |
| NCT06948188 | Not specified | NOT_YET_RECRUITING | Identification of Subpopulations of Patients With Cholinergic Urticaria Based on Infrared Exposure Test Results. |
| NCT06201780 | Not specified | UNKNOWN | Assessment of Serum Levels of Janus Kinase 1 and 2 in Patients With Cholinergic Urticaria |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DUPILUMAB | 4 | 1 |
| BARZOLVOLIMAB | 3 | 1 |
| LIGELIZUMAB | 3 | 1 |
Related Atlas pages
- Drugs: Dupilumab, Barzolvolimab, Ligelizumab